Leading brokers name 3 ASX shares to buy today

Here's why brokers rate these ASX shares as buys…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

A white and black clock face is shown with Time to Buy written.

Image source: Getty Images

News Corp (ASX: NWS)

According to a note out of Goldman Sachs, its analysts have retained their conviction buy rating and increased their price target on this media giant's shares to $44.50. This follows the release of its full year result last week. And while News Corp fell a touch short of its expectations, the broker remains very positive on its outlook. It is forecasting operating earnings growth of 17% in FY 2022. It also believes share buybacks could unlock value for shareholders. The News Corp share price is trading at $32.37 today.

REA Group Limited (ASX: REA)

A note out of Morgan Stanley reveals that its analysts have retained their overweight rating and $185.00 price target on this property listings company's shares. Morgan Stanley was pleased with REA's FY 2021 result. And while it suspects that its first half result could be a touch softer than expected in FY 2022 because of lockdowns, it expects listing volumes to rebound quickly. In light of this, it appears to believe any short term share price weakness would be a buying opportunity. The REA share price is fetching $154.24 today.

ResMed Inc (ASX: RMD)

Analysts at Morgans have retained their add rating and lifted their price target on this sleep treatment company's shares by almost 42% to $41.34. This follows the release of a stronger than expected fourth quarter update last week. It also notes that management expects a US$300 million to US$350 million revenue benefit in FY 2022 from the product recall by rival Philips. The broker notes that this has led to unsatisfied demand everywhere. Though, Morgans acknowledges that bottlenecks in the supply chain could limit the benefit from pent-up demand for devices. The ResMed share price is trading at $37.77 today.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended REA Group Limited and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

gold, gold miner, gold discovery, gold nugget, gold price,
Broker Notes

With the gold price up on Monday, are Northern Star shares a good buy now?

A leading analyst provides his outlook for Northern Star’s shares.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

An oil refinery worker stands in front of an oil rig with his arms crossed and a smile on his face.
Broker Notes

Up 23% this year, should I buy Woodside shares today?

A leading analyst provides his outlook for Woodside’s outperforming shares.

Read more »

Woman and man calculating a dividend yield.
Broker Notes

Buy, hold, sell: JB Hi-Fi, Westpac, Santos shares

Experts explain their buy, hold, and sell recommendations on these 3 ASX 200 shares.

Read more »

A person leans over to whisper a secret to a colleague during a meeting.
Broker Notes

Buy, hold, sell: Life360, Woodside, CSL shares

The market is lower today as two experts explain their ratings on these three ASX 200 shares. 

Read more »

A group of business people sit dejectedly around a table, each expressing desolation, sadness, and disappointment by holding their head in their hands, casting their gazes down and looking very glum.
Broker Notes

Why CSL, Westpac, and this big-name ASX 200 share could be sells

Experts are feeling bearish about these big names. Let's find out why.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Broker Notes

Experts name 3 ASX 200 shares to buy

These shares are highly rated by experts for different reasons.

Read more »

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices.
Broker Notes

8 ASX shares with 30% to 220% upside ahead: Experts

We reveal the 12-month share price targets just set by brokers on these eight ASX stocks.

Read more »